Helicobacter. Helicobacter pylori [H.pylori] as the cause of diseases classified to other chapters
Conditions
Interventions
Treatment - Drugs
Intervention 1: Intervention group: quadruple antibiotic regimen include: amoxicillin 1000 mg bid, metronidazol 500 mg bid, bismuth subcitrate 2 tablets bid, pantoprazole 40 mg bid for a two-week peri
Intervention group: quadruple antibiotic regimen include: amoxicillin 1000 mg bid, metronidazol 500 mg bid, bismuth subcitrate 2 tablets bid, pantoprazole 40 mg bid for a two-week period.
Control group: triple antibiotic regimen include: amoxicillin 1000 mg bid, clarithromycin 500 mg bid, pantoprazole 40 mg bid for a two-week period.
Sponsors
Vice Chancellor for research of Yasuj University of Medical Sciences
Eligibility
Sex/Gender
All
Age
15 Years to 80 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Patients aged 15- 80 years; patients with dyspepsia Exclusion criteria: Patients with history of H. pylori eradication treatment;taking antibiotics in the last month; gastrointestinal bleeding; chronic pulmonary, liver or renal diseases; history of gastric surgery; pregnancy; recent consumption of NSAID; taking PPI or H2 receptor antagonists in the previous week
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| H pylori eradication. Timepoint: 6 week after treatment. Method of measurement: Stool H pylori antigen. | — |
Secondary
| Measure | Time frame |
|---|---|
| Drug reaction. Timepoint: Until 6 weeks after treatment. Method of measurement: Questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMoslem Sedaghattalb
Yasuj University of Medical Science
Outcome results
None listed